Skip Navigation
Search Menu

Print This Page
Share this page: More

T32 Training Program in Hematology

Program Directors

Robert Brodsky, MD, Program Director, Professor of Medicine and Oncology - Aplastic anemia, paroxysmal noctural hemoglobinuria (PNH), and other bone marrow failure disorders

Linzhao Cheng, PhD, Program Co-Director, Professor of Medicine - Human stem cell biology and engineering, hematopoiesis (blood-forming)

Carol Greider, PhD, Program Co-Director, Professor of Molecular Biology and Genetics - Telomere function, the regulation of telomere length and the biochemistry of telomerase

Richard Jones, MD, Program Co-Director, Professor of Oncology, Medicine, and Pathobiology - Hematopoiesis, blood and marrow transplantation, hematologic malignancies

Program Faculty

Richard Ambinder, MD, PhD, Professor of Oncology - Treatment of lymphoma and Kaposi's sarcoma and in development of new strategies for prevention of lymphoma.  Treatment of Hodgkin's disease

Mary Armanios, MD, Associate Professor of Oncology - Syndromes of telomere shortening which capture both the degenerative and cancer-prone phenotypes of aging

Kathleen Burns, MD, PhD, Associate Professor of Pathology - Studying roles mobile DNAs play in human disease and developing new reagents and high throughput technologies

James Casella, MD, Professor of Pediatrics and Oncology - Cellular and molecular basis of pediatric blood-borne diseases, inherited blood disorders, hemophilia, stroke, sickle cell

Andrew Feinberg, MD, MPH, Professor of Molecular Medicine, Medicine, Oncology, and Molecular Biology and Genetics - Epigenetics and DNA methylation, genomic imprinting, cancer biology, genomic Imprinting

Haig Kazazian, MD, Professor of Pediatrics - Biology of L1 retrotransposons in human beings and mice; Gene therapy of hemophilia A using AAV vectors

Thomas Kickler, MD, Professor of Medicine, Oncology, and Pathology - Hemostasis and platelet disorders

Mark Levis, MD, PhD, Associate Professor of Oncology and Medicine - Identify and validate novel molecular therapeutic targets in hematopoietic malignancies, identification and preclinical development of novel targeted therapies

William Matsui, MD, Associate Professor of Oncology - Cancer stem cells

Linda Resar, MD, Associate Professor of Medicine, Oncology, and the Institute for Cellular Engineering - The molecular mechanisms leading to cancer, blood diseases in young adults, sickle cell anemia and other hemoglobinopathies, hemophilia and other coagulopathies

Jonathan Schneck, MD, PhD, Professor of Pathology, Medicine, and Oncology - T cell immunology

Gregg Semenza, MD, PhD, Professor of Pediatrics, Medicine, Oncology, and Radiation Oncology - Molecular mechanisms underlying angiogenesis and vascular remodeling in ischemic cardiovascular disease and cancer 

Jerry Spivak, MD, Professor of Medicine and Oncology - The chronic myeloproliferative disorders, polycythemia vera, idiopathic myelofibrosis, essential thrombocytosis, hypereosinophilia, stocytosis; erythrocytosis and erythropoietin physiology

Zack Wang, PhD, Assistant Professor of Medicine - Stem cell biology, developmental biology, vascular biology

Advisory Committee Members

Adult Hematology:  Robert Brodsky, MD, Linzhao Cheng, PhD, Linda Resar, MD

Diversity Committee:  Enid Neptune, MD

Hematologic Malignancies:  Richard Jones, MD, Richard Ambinder, MD, PhD

Molecular Biology and Genetics:  Carol Greider, PhD

Molecular Medicine:  Andrew Feinberg, MD, MPH